No. |
Product Name |
CAS No. |
Spec |
Price |
|
1344509 |
Iodoquinol (100 mg) |
83-73-8 |
|
|
1344600 |
Iohexol (200 mg) |
66108-95-0 |
|
|
1344622 |
Iohexol Related Compound A (100 mg) (5-(acetylamino)-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) |
N/A |
|
|
1344644 |
Iohexol Related Compound B (50 mg) (5-amino-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) |
76801-93-9 |
|
|
1344666 |
Iohexol Related Compound C (50 mg) (N,N’-bis(2,3-dihydroxypropyl)-5-nitro-1,3-benzenedicarboxamide) |
N/A |
|
|
1344702 |
Iopamidol (200 mg) |
60166-93-0 |
|
|
1344724 |
Iopamidol Related Compound A (50 mg) (N,N’-Bis-(1,3-dihydroxy-2-propyl)-5-amino-2,4,6-triiodoiso-phthalamide) |
60166-98-5 |
|
|
1344735 |
Iopamidol Related Compound B (50 mg) (5-Glycolamido-N,N’-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodoisophthalamide) |
N/A |
|
|
1344746 |
Iopamidol Related Compound C (40 mg) (4-chloro-N1, N3-bis(1,3-dihydroxypropan-2-yl)-5-(S)-lactamido-2,6-diiodoisophthalamide) |
N/A |
|
|
1344804 |
Iopromide (400 mg) |
73334-07-3 |
|
|
1344826 |
Iopromide Related Compound A (50 mg) (5-Amino-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-1,3-benzenedicarboxamide) |
N/A |
|
|
1344837 |
Iopromide Related Compound B (50 mg) (5-(Acetylamino)-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-1,3-benzenedicarboxamide) |
N/A |
|
|
1345002 |
Iothalamic Acid (200 mg) |
2276-90-6 |
|
|
1345104 |
Ioversol (200 mg) |
87771-40-2 |
|
|
1345115 |
Ioversol Related Compound A (50 mg) (5-Amino-N,N’-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide) |
76801-93-9 |
|
|
1345126 |
Ioversol Related Compound B (50 mg) (N,N’-bis(2,3-dihydroxypropyl)-5-[(N-(2-hydroxyethyl)-carbamoyl)methoxy]-2,4,6-triiodoisophthalamide) |
N/A |
|
|
1345159 |
Ioxaglic Acid (100 mg) |
59017-64-0 |
|
|
1345206 |
Ioxilan (400 mg) |
107793-72-6 |
|
|
1345228 |
Ioxilan Related Compound A (100 mg) (5-amino-2,4,6-triiodo-3 N-(2-hydroxyethyl)carbamoyl benzoic acid) |
22871-58-5 |
|
|
1347008 |
Ipodate Sodium (200 mg) |
1221-56-3 |
|
|
|
|